MAO-B level is found to be associated with neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease and the selective inhibition of MAO-B is applied to the treatment of those two diseases9, 10, 11, 12, 13, 14. This evidence concerns the gene MAOB and early-onset autosomal dominant Alzheimer disease.